Aura Biosciences, Inc. Stock Price, News & Analysis

Aura Biosciences Inc. (NASDAQ: AURA) will host a virtual Investor Day on March 22, 2022, from 11:00 a.m. to 12:30 p.m. ET. The event will feature presentations by notable ocular oncology experts, Dr. Carol Shields and Dr. Hans Grossniklaus, focusing on choroidal melanoma and the novel therapy AU-011. The company plans to finalize the treatment regimen for AU-011 and initiate a pivotal program in the latter half of 2022. The event can be accessed via phone or through a live webcast on Aura's investor website.

Aura Biosciences Inc. (NASDAQ: AURA) presented preclinical data for its first Virus-Like Drug Conjugate (VDC) candidate, AU-011, at the 2022 American Association for Cancer Research Annual Meeting. Targeting aggressive cancers like primary choroidal melanoma and non-muscle invasive bladder cancer, results indicate AU-011's potential effectiveness across multiple solid tumor types. The findings enhance understanding of tumor cell biology and signal opportunities for expanding clinical trials. The company is focused on developing AU-011 for ocular and potentially broader oncological applications.

Aura Biosciences Inc. (NASDAQ: AURA), a biotechnology firm focused on innovative virus-like drug conjugate (VDC) therapies for cancer, announced CEO Elisabet de los Pinos will join a panel discussion on “Auditory and Ophthalmology” at the 42nd Annual Cowen Virtual Health Care conference on March 7, 2022, at 2:10 p.m. ET. A live webcast will be available on the company’s website, with a replay archived for 90 days. Aura’s lead candidate, AU-011, targets ocular cancers and is undergoing a Phase 2 clinical trial for choroidal melanoma, a severe eye cancer.

Aura Biosciences (NASDAQ: AURA) announced its upcoming Phase 1 clinical trial for AU-011, a virus-like drug conjugate targeting Non-Muscle Invasive Bladder Cancer (NMIBC). This follows the presentation of promising preclinical data at the 2022 ASCO Genitourinary Cancer Symposium. AU-011 shows consistent tumor cell binding and cytotoxicity, indicating its potential efficacy across all tumor grades. The trial is set to begin in the second half of 2022, focusing on addressing the unmet need for effective treatments in NMIBC.

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, will have CEO Elisabet de los Pinos participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 8:40 a.m. ET. The discussion will be accessible via a live webcast on the company's Investors & Media page, with a replay available for 90 days. Aura is focusing on developing its lead therapy AU-011 for ocular cancers, including a Phase 2 trial for choroidal melanoma.

Aura Biosciences Inc. (NASDAQ: AURA) announced its financial results for Q3 2021, reporting a net loss of $8.8 million compared to $3.6 million in Q3 2020. The company successfully completed a public offering, raising approximately $86.9 million to support the development of its lead therapy, AU-011, for choroidal melanoma. Significant data from Phase 1b/2 trials highlighted a tumor growth reduction of 0.483 mm/year and a 64% tumor control rate. Aura plans to initiate pivotal programs in 2022 and expand its oncology pipeline into non-muscle invasive bladder cancer.

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company, will have CEO Elisabet de los Pinos participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx conference on November 30, 2021, at 2:15 p.m. ET. This event will showcase Aura’s innovative virus-like drug conjugate (VDC) therapies targeting ocular and urologic cancers. A live webcast will be available on the company’s website, with an archived replay for 90 days post-event. Aura aims to revolutionize cancer treatment, focusing initially on ocular oncology with promising data from its lead product candidate, AU-011.

Aura Biosciences presented critical data on AU-011, its virus-like drug conjugate for treating choroidal melanoma, at the AAO 2021 Annual Meeting. The Phase 1b/2 trial showed a statistically significant tumor growth reduction of -0.483 mm/year (p = 0.018) and a 64% tumor control rate among 14 patients. Visual acuity preservation was achieved in 71% of cases. Furthermore, preliminary findings from the ongoing Phase 2 trial with suprachoroidal administration reported no serious adverse events. These results underscore AU-011’s potential as a safe first-line therapy for this aggressive cancer.

Aura Biosciences, a clinical-stage oncology firm, has priced its initial public offering (IPO) at $14.00 per share for 5,400,000 shares, aiming to raise approximately $75.6 million. The offering is scheduled to begin trading on the Nasdaq Global Market under the ticker AURA on October 29, 2021, with the closing date set for November 2, 2021. Aura has also granted underwriters a 30-day option for an additional 810,000 shares. The funds will support the development of its innovative virus-like drug conjugate therapies for various cancer indications.